2018
DOI: 10.3960/jslrt.18034
|View full text |Cite
|
Sign up to set email alerts
|

Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma

Abstract: The c-fms proto-oncogene is also known as macrophage colony stimulating factor receptor (M-CSFR) or colony-stimulating factor-1 receptor (CSF-1R), and is expressed on several types of malignant tumor cells and myeloid cells. In the present study, we found that overexpression of M-CSFR was present in adult T-cell leukemia/lymphoma (ATLL) cases. M-CSFR signaling was associated with lymphoma cell proliferation, and M-CSFR inhibition induced apoptosis in lymphoma cells. The ATLL cell line ATL-T expressed M-CSF/CSF… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 18 publications
(16 citation statements)
references
References 41 publications
1
15
0
Order By: Relevance
“…[16][17][18][19][20][21][22][23] In this regard, little is known about the expression of IL-34 in hematological malignancies, except for a recent study by Komohara et al that described the expression of IL-34 in adult T-cell leukemia/lymphoma. 27 Similarly, we found here that the expression of IL-34 can be observed in MM cells and varies among MM patients, showing high levels in some cases but being absent in others. In the murine MOPC315.BM MM model, we found that IL-34 importantly contributes to MM-induced osteolytic disease.…”
Section: Discussionsupporting
confidence: 84%
“…[16][17][18][19][20][21][22][23] In this regard, little is known about the expression of IL-34 in hematological malignancies, except for a recent study by Komohara et al that described the expression of IL-34 in adult T-cell leukemia/lymphoma. 27 Similarly, we found here that the expression of IL-34 can be observed in MM cells and varies among MM patients, showing high levels in some cases but being absent in others. In the murine MOPC315.BM MM model, we found that IL-34 importantly contributes to MM-induced osteolytic disease.…”
Section: Discussionsupporting
confidence: 84%
“…To investigate whether the CSF1/CSF1R axis impacts tumor cell growth, 3 × 10 3 tumor cells were seeded at 96-well plates, and 24 h later, they were treated with CSF1 (10–20 ng/mL), BLZ945 (670 nM) or the vehicle for 24 h. To investigate whether IL34 (an alternative ligand of CSF1R) might affect tumor cell viability, we repeated experiments using the vehicle, IL34 (1 and 10 μg/mL, found to affect lymphoma tumor cell growth, [ 23 ]) and BLZ945. Cell viability was subsequently evaluated by MTS reduction (Promega, Madison, WI, USA).…”
Section: Methodsmentioning
confidence: 99%
“…A study using GW2580 shows that inhibiting CSF1R could impair the progression of hepatocellular carcinoma in mice 203 . While it has been demonstrated that inhibiting CSF1R via PLX3397 (pexidartinib) 204 has antitumor effects in adult T-cell leukemia/lymphoma (ATLL) by inducing ATL-T cells to undergo apoptosis and reducing the expression of PD-L1/L2 205 , another study shows that PLX3397 induces pancreatic ductal adenocarcinoma by upregulating T-cell checkpoint molecules 206 . BLZ945 inhibits glioma progression 207 and delays cervical and mammary tumor growth 208 .…”
Section: Diseases and Therapeutic Applications Of Csf1r Inhibitionmentioning
confidence: 99%